Costa Rican registry of IL-23 inhibitors for psoriatic disease
Treatments studied
Part of Skin clinical trials.
This study is a registry that collects information from patients with psoriatic disease who are treated with IL-23 inhibitors (guselkumab or risankizumab) in Costa Rica. It aims to track how these treatments work in real-life settings to improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of psoriasis (any type) or psoriatic arthritis.
- You must be currently taking either guselkumab or risankizumab (IL-23 inhibitors).
- You must be treated at a participating public health center in Costa Rica.
- Your medical records (history, follow-up notes, and labs) must be available for the registry.
- You must be 12 years of age or older, any gender.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
This trial is a registry that collects information from adults with plaque psoriasis or psoriatic arthritis who are starting a new biologic or other systemic treatment. It helps researchers understand how these treatments are used in real life and what outcomes they may have.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study tests if guselkumab can reduce pain and inflammation in people with psoriatic arthritis. You may join if standard treatments have not worked well enough or caused side effects.
This study is a registry in Costa Rica that collects information about people diagnosed with generalized pustular psoriasis (GPP). It helps doctors learn more about this rare skin condition and how it affects patients over time.
This study looks at how psoriasis affects children in Costa Rica, including what treatments they receive. It helps doctors understand the condition better and improve care for kids with psoriasis.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.